small molecule dual BTK/LCK inhibitors (Aegera)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namesmall molecule dual BTK/LCK inhibitors (Aegera)
Drug Alias NameBruton's tyrosine kinase/lymphocyte-specific protein tyrosine kinase inhibitors (Aegera)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitorsTyrosine-protein kinase LCK inhibitors
TargetsTyrosine-protein kinase BTKTyrosine-protein kinase LCK
Therapy Area/IndicationsInflammationAutoimmune DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAegera Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAegera Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsInflammationAutoimmune DiseasesNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A